

5. (Currently Amended) A method of treating ~~The use of a compound, which is a serotonin reuptake inhibitor, and another compound, which is a GABA_B receptor antagonist, inverse agonist or partial agonist for the preparation of a pharmaceutical composition for the treatment of depression, anxiety disorders and or other affective disorders, such as generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post traumatic stress disorder and social anxiety disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder, drug abuse or any other disorder responsive to serotonin reuptake inhibitors comprising administering to a person in need thereof a therapeutically effective amount of a~~ compound, which is a serotonin reuptake inhibitor, and a compound, which is a GABA_B receptor antagonist, inverse agonist or partial agonist.

6. (Currently Amended) The use method according to claim 1 ~~any of claims 1-5~~ wherein the serotonin reuptake inhibitor is a selective serotonin reuptake inhibitor ~~is used.~~

7. (Currently Amended) The use method according to claim 1 ~~any of claims 1-5~~ wherein ~~a compound, which is the~~ GABA_B receptor antagonist, inverse agonist or partial agonist is selective for the GABA_B receptor; ~~is used.~~

8. (Currently Amended) The use method according to claim 1 ~~any of claims 1-5 or 7~~ wherein an antagonist or an inverse agonist at the GABA_B receptor is used.

9. (Currently Amended) The use method according to claim 8 wherein a GABA_B receptor antagonist is used.

10. (Currently Amended) The use method according to claim 1 ~~any of claims 1-6~~ wherein the ~~SRI~~ serotonin reuptake inhibitor is ~~elected~~ selected from citalopram, escitalopram, fluoxetine, sertraline, paroxetine, fluvoxamine, venlafaxine, dapoxetine, duloxetine, vilazodone, nefazodone, imipramin, femoxetine and clomipramine.

23. (Currently Amended) The A method according to claim 22 wherein the compound has an affinity in step (b) of less than 500 nM.

24. (Currently Amended) The A method according to claim ~~any of claims 22 and 23~~, wherein the compound has an affinity in step (b) of less than 100 nM.

25. (Currently Amended) A compound identified according to the method of claim 22 ~~any of the claims 22-24~~.

26. (New) The method according to claim 1, wherein the anxiety disorders and other affective disorders are selected from generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post traumatic stress disorder and social anxiety disorder.

27. (New) The method according to claim 1, wherein the eating disorder is selected from bulimia, anorexia, and obesity.

28. (New) The method according to claim 3, wherein the anxiety disorders and other affective disorders are selected from generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post traumatic stress disorder and social anxiety disorder.

29. (New) The method according to claim 3, wherein the eating disorder is selected from bulimia, anorexia, and obesity.

30. (New) The pharmaceutical composition according to claim 20 wherein the active ingredients are contained in discrete dosage forms.